A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.

Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.

ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.

Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.